U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H22N4O3S
Molecular Weight 398.479
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOTULETINIB

SMILES

CNC(=O)C1=NC=CC(OC2=CC=C3N=C(N[C@@H]4CCCC[C@H]4O)SC3=C2)=C1

InChI

InChIKey=ADZBMFGQQWPHMJ-RHSMWYFYSA-N
InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H22N4O3S
Molecular Weight 398.479
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24056773 | https://www.ncbi.nlm.nih.gov/pubmed/21653914

BLZ 945, an orally active antagonist of the colony-stimulating factor1 receptor (CSF1R), is being developed by Novartis and Celgene Corporation for the treatment of advanced solid tumors and tumor-induced osteolytic lesions in bone and skeletal-related events. Phase I/II development for solid tumors is underway in the US, Italy, Spain, and Singapore. Preclinical trials were ongoing for tumor-induced osteolysis in Europe and the US. However, no recent reports of development had been identified for this indication.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.2 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day multiple, oral
RP2D
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite.
2015 Feb
Patents

Sample Use Guides

Mice received 200 mg per kg body weight BLZ945 or vehicle (20% Captisol) by oral gavage once daily. BLZ945 was formulated in 20% Captisol at a concentration of 12.5 mg ml−1. Mice were dosed daily for 15 d, and tumor growth was monitored every 5 d by bioluminescence imaging.
Route of Administration: Oral
Treatment of wild-type (WT) bone marrow–derived macrophages (BMDMs) with BLZ945 inhibited CSF-1–dependent prolifera¬tion (half-maximum effective concentration (EC50) = 67 nM) and decreased CSF-1R phosphorylation, similarly to blockade with CSF-1R–specific antibody. Primary bone marrow-derived macrophages (BMDMs) were cultured in the absence of CSF-1 for 12 hours prior to stimulation, followed by CSF-1 addition for the indicated time points (1.5, 3 and 5 minutes).
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:05:55 GMT 2023
Edited
by admin
on Sat Dec 16 11:05:55 GMT 2023
Record UNII
7W3V82OQ0P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOTULETINIB
INN  
Official Name English
2-PYRIDINECARBOXAMIDE, 4-((2-(((1R,2R)-2-HYDROXYCYCLOHEXYL)AMINO)-6-BENZOTHIAZOLYL)OXY)-N-METHYL-
Systematic Name English
sotuletinib [INN]
Common Name English
BLZ-945
Common Name English
CSF-1R INHIBITOR BLZ945
Common Name English
BLZ 945 [WHO-DD]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 897222
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
Code System Code Type Description
FDA UNII
7W3V82OQ0P
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY
CAS
953769-46-5
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY
PUBCHEM
46184986
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY
SMS_ID
300000039089
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY
INN
11802
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY
NCI_THESAURUS
C129653
Created by admin on Sat Dec 16 11:05:55 GMT 2023 , Edited by admin on Sat Dec 16 11:05:55 GMT 2023
PRIMARY NCIT
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> ACTIVATOR
Related Record Type Details
ACTIVE MOIETY